CHIP formulary update

(2nd Quarter 2022 effective January 1, 2023)

The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have been approved by the U.S. Food and Drug Administration (FDA). The formulary is updated on a quarterly basis or when new generic or brand-name medications become available and as discontinued drugs are removed from the marketplace.

The Capital BlueCross closed formulary serves as a reference for Exchange/Marketplace prescription drug benefit designs.

A Value formulary provides access to generic, brand preferred and select brand non-preferred medications. Under a Closed formulary, only select brand non-preferred drugs (non-formulary drugs) are covered unless approved via a Non-Formulary Consideration Process. The provider may request that coverage be granted when medically necessary. The Non-Formulary Consideration Process may require the trial and failure of 2 formulary alternatives (if 2 are available) prior to approval of the non-formulary medication. Approvals will be member-and drug-specific. Each unique non-formulary drug exception must be reviewed and approved separately.

The following medications have been added to the Quantity level limits (QLL) program.

Products going obsolete

Drug class/Drug

Current tier

New tier

Effective date

glatiramer acetate

SP

Exclude

5/16/2022

glycopyrrolate tbdp

GNP

Exclude

10/1/2022

testosterone gel

GNP

Exclude

1/1/2023

torsemide tabs

GP

Exclude

10/1/2022

varenicline tartrate tabs

PHC

Exclude

1/1/2023

Quantity level limit (QLL) program

Effective January 1, 2023

Drug class/Drug

FIASP

FIASP

HUMALOG

HUMALOG

HUMALOG

HUMALOG MIX 50/50

HUMALOG MIX 75/25

HUMALOG MIX 75/25

INSULIN ASPART

INSULIN ASPART PROTAMINE/INSULIN ASPART

INSULIN LISPRO

INSULIN LISPRO

INSULIN LISPRO

INSULIN LISPRO JUNIOR KWIKPEN

INSULIN LISPRO JUNIOR KWIKPEN

INSULIN LISPRO KWIKPEN

INSULIN LISPRO KWIKPEN

INSULIN LISPRO PROTAMINE

NOVOLIN 70/30

NOVOLIN N

NOVOLIN R

NOVOLIN R

NOVOLOG

NOVOLOG 70/30

Impacted members will be notified prior to change